• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用时间序列分析预测非转移性 ER+ 乳腺癌绝经后妇女的健康相关生活质量:教程和案例研究。

Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study.

机构信息

Pharmaceutical Outcomes & Policy (POP), College of Pharmacy, HPNP 3338, University of Florida, 1225 Center Drive, Gainesville, FL, 32610, USA.

Department of Pharmaceutical Outcomes and Policy College of Pharmacy, HPNP 2309, University of Florida, 1225 Center Drive Gainesville, FL, 32610, USA.

出版信息

Res Social Adm Pharm. 2020 Aug;16(8):1095-1099. doi: 10.1016/j.sapharm.2019.11.009. Epub 2019 Nov 18.

DOI:10.1016/j.sapharm.2019.11.009
PMID:31753693
Abstract

BACKGROUND

Time series models are widely used forecasting techniques in health care for long time series and are typically built in commercial statistical packages. However, for short time series data, such as health-related quality of life (HRQoL), guidance on how to select and use appropriate time series models is lacking. This tutorial provides a step-by-step guide adopting a time series analysis framework for HRQoL forecasting.

OBJECTIVE

We walk through a case study examining the forecasting of the effects of adjuvant endocrine therapy on the HRQoL of post-menopausal women with non-metastatic ER + breast cancer using data from the HRQoL sub-protocol of the Tamoxifen arm of the Arimidex, tamoxifen, alone or in combination (ATAC) trial.

METHODS

The forecasting of HRQoL consists of four steps: 1) data extraction and accuracy check, 2) forecasting horizon definition and identification of data pattern, 3) forecasting model identification and fitting using five forecasting approaches appropriate for short time series ((i) double exponential smoothing, (ii) double moving average, (iii) fuzzy forecasting, (iv) grey forecasting, and (v) Volterra series), 4) forecasting model selection. A user-friendly visual basic for applications (VBA) Excel add-in is made available to interested users to facilitate the application of the tutorial.

RESULTS

The Grey method and Volterra series appeared to be good candidates to forecast the effects of adjuvant endocrine therapy on the HRQoL of post-menopausal women with non-metastatic ER + breast cancer enrolled in the ATAC trial.

CONCLUSION

It is feasible to forecast the effects of treatments on HRQOL even when the time series is short.

摘要

背景

时间序列模型是医疗保健领域中广泛用于长期时间序列预测的技术,通常在商业统计软件包中构建。然而,对于短期时间序列数据,例如健康相关生活质量(HRQoL),缺乏关于如何选择和使用适当的时间序列模型的指导。本教程提供了一个采用时间序列分析框架进行 HRQoL 预测的分步指南。

目的

我们通过一个案例研究,使用来自 ATAC 试验中他莫昔芬手臂的 HRQoL 子协议中的数据,探讨辅助内分泌治疗对非转移性 ER+乳腺癌绝经后妇女 HRQoL 的影响预测。

方法

HRQoL 的预测包括四个步骤:1)数据提取和准确性检查,2)预测范围定义和数据模式识别,3)使用适用于短期时间序列的五种预测方法(i)双指数平滑,(ii)双移动平均,(iii)模糊预测,(iv)灰色预测和(v)Volterra 系列)识别和拟合预测模型,4)预测模型选择。为有兴趣的用户提供了一个用户友好的 Visual Basic for Applications(VBA)Excel 加载项,以方便本教程的应用。

结果

灰色方法和 Volterra 系列似乎是预测辅助内分泌治疗对 ATAC 试验中入组的非转移性 ER+乳腺癌绝经后妇女 HRQoL 影响的良好候选方法。

结论

即使时间序列较短,也可以预测治疗对 HRQOL 的影响。

相似文献

1
Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study.使用时间序列分析预测非转移性 ER+ 乳腺癌绝经后妇女的健康相关生活质量:教程和案例研究。
Res Social Adm Pharm. 2020 Aug;16(8):1095-1099. doi: 10.1016/j.sapharm.2019.11.009. Epub 2019 Nov 18.
2
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.早期乳腺癌辅助治疗5年后,ATAC(“阿那曲唑”、他莫昔芬单药或联合用药)试验中绝经后女性的生活质量。
Breast Cancer Res Treat. 2006 Dec;100(3):273-84. doi: 10.1007/s10549-006-9260-6. Epub 2006 Jun 21.
3
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.辅助性他莫昔芬或阿那曲唑治疗后转移性乳腺癌的序贯激素治疗
Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. doi: 10.1023/a:1025459232293.
4
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.绝经后女性ATAC辅助性乳腺癌试验:子宫内膜亚方案基线数据
BJOG. 2003 Dec;110(12):1099-106.
5
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.“瑞宁得”(阿那曲唑)与他莫昔芬作为早期乳腺癌绝经后女性辅助治疗的疗效概述
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):399-403. doi: 10.1016/s0960-0760(03)00350-9.
6
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.阿那曲唑与他莫昔芬作为早期雌激素受体阳性乳腺癌患者初始辅助治疗的获益及预期成本效益
Cancer. 2004 Sep 15;101(6):1311-22. doi: 10.1002/cncr.20492.
7
Current and future status of adjuvant therapy for breast cancer.乳腺癌辅助治疗的现状与未来发展态势
Cancer. 2003 Feb 1;97(3 Suppl):880-6. doi: 10.1002/cncr.11124.
8
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.来自ATAC试验的三年随访足以改变临床实践:一场辩论。
Breast Cancer Res Treat. 2003;80 Suppl 1:S3-11; discussion S13-8. doi: 10.1023/a:1025455130476.
9
Emerging role of aromatase inhibitors in the adjuvant setting.芳香化酶抑制剂在辅助治疗中的新作用。
Am J Clin Oncol. 2003 Aug;26(4):S27-33. doi: 10.1097/00000421-200308001-00005.
10
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.ATAC(“阿那曲唑”、他莫昔芬,单独使用或联合使用)辅助性乳腺癌试验:关于经阴道超声检查和诊断性宫腔镜检查有效性的子宫内膜亚方案基线数据。
Hum Reprod. 2005 Jan;20(1):294-301. doi: 10.1093/humrep/deh567. Epub 2004 Oct 28.

引用本文的文献

1
Emotion Regulation Flexibility and Electronic Patient-Reported Outcomes: A Framework for Understanding Symptoms and Affect Dynamics in Pediatric Psycho-Oncology.情绪调节灵活性与电子患者报告结局:理解儿科心理肿瘤学中症状及情感动态的框架
Cancers (Basel). 2022 Aug 11;14(16):3874. doi: 10.3390/cancers14163874.